See every side of every news story
Published loading...Updated

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Summary by Intelligence360 News
December 30, 2024 08:00 AM Eastern Standard Time QUEENSBURY, N.Y.–(BUSINESS WIRE)–Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which resulted in $16.3 million of funding. Approximately 6.6% of the warrants exercised were subject to cashless exercise …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Intelligence360 News broke the news in on Tuesday, January 7, 2025.
Sources are mostly out of (0)